HDBuzz

⏱️8 min read | What if Huntington’s disease changes how we “see” the world before we even notice symptoms? New research suggests visual thinking skills may help track HD progression over time.

August was another busy month for HD research! Learnings from past trials, new approaches to huntingtin lowering, the start of INSIGHTT and PRECISE-HD, three packed days at HD2026, and the HDBuzz Prize: we’ve got you covered. 

The first participant has now been dosed in the Phase 3 PRECISE-HD trial of pridopidine for HD. The study will test whether the drug can slow disease progression in people most likely to benefit

⏱️5 min read | New research points to HTT1a, a toxic shortened form of huntingtin, as a key driver of disease and a promising therapeutic target in HD.

A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an important new arrow to the HD drug development quiver.